Effects of Pyrotinib Combined with Paclitaxel-based Chemotherapy Regimen on Immune Function and Prognosis in Patients with Advanced HER2-positive Breast Cancer
Objective To explore the effects of pyrotinib combined with paclitaxel-based chemotherapy regimen on im-mune function and prognosis in patients with advanced human epidermal growth factor receptor-2(HER2)positive breast cancer(BC).Methods A total of 62 patients with advanced HER2-positive BC were enrolled.According to random number table meth-od,they were divided into the observation group and the control group,31 cases in each group.The control group was given pacli-taxel-based chemotherapy regimen,while the observation group was additionally given pyrotinib.After 12 weeks of treatment,dis-ease control rate(DCR)was evaluated.The levels of T lymphocyte subsets before and after treatment,and incidence of adverse re-actions during treatment were compared between the two groups.The median progression-free survival(PFS)and 12-month surviv-al rate were analyzed by Kaplan-Meier method.Results DCR in observation group was significantly higher than that in control group(70.97％vs 45.16％,P＜0.05).After treatment,levels of CD3+and CD4+in observation group were higher than those in control group,while CD4+/CD8+was lower than that in control group(P＜0.05).There was no significant difference in the inci-dence of adverse reactions(liver function impairment,leukopenia,gastrointestinal reactions,neurotoxic reactions,rash)between the two groups during treatment(P＞0.05).Kaplan-Meier survival analysis showed that 12-month survival rate in observation group was higher than that in control group(77.41％vs 54.83％,x2=3.946,P＜0.05),and median PFS was higher than that in control group[(10.79±0.61)months vs(8.36±0.75)months,t=4.793,P＜0.05].Conclusion Pyrotinib combined with paclitaxel-based chemotherapy regimen can increase DCR,improve T lymphocyte immune function and prolong PFS in pa-tients with advanced HER2-positive BC,which is safe and effective.
万方数据
维普
